Gilgamesh is a serious mental health science focused, preclinical biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCE's) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/06/21 | $27,000,000 | Series A |
Gron Ventures JLS Fund Noetic Psychedelic Fund Palo Santo Investors Prime Movers Lab  Route 66 Ventures | undisclosed |
| 12/15/22 | $39,000,000 | Series B |
Alumni Ventures Group Gron Ventures JLS Fund Negev Capital Palo Santo Investors Prime Movers Lab Route 66 Ventures Satori Capital | undisclosed |
